Saybrook Capital Bristol Myers Squibb CO Transaction History

Saybrook Capital

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$40.25 - $52.99 $241,500 - $317,940	-6,000 Reduced 40.37%	8,863 $368,000
Q1 2023 Apr 28, 2023	SELL	$65.71 - $74.53 $5,716 - $6,484	-87 Reduced 0.58%	14,863 $1.03 Million
Q4 2022 Feb 08, 2023	BUY	$68.48 - $81.09 $5,957 - $7,054	87 Added 0.59%	14,950 $1.08 Million
Q1 2022 May 05, 2022	SELL	$61.48 - $73.72 $5,102 - $6,118	-83 Reduced 0.56%	14,863 $1.09 Million
Q4 2021 Jan 28, 2022	SELL	$53.63 - $62.52 $429 - $500	-8 Reduced 0.05%	14,946 $932,000
Q3 2021 Nov 02, 2021	SELL	$59.17 - $69.31 $2,544 - $2,980	-43 Reduced 0.29%	14,954 $885,000
Q2 2021 Jul 20, 2021	BUY	$61.91 - $67.42 $8,295 - $9,034	134 Added 0.9%	14,997 $1 Million
Q1 2020 May 04, 2020	BUY	$46.4 - $67.43 $281,323 - $408,828	6,063 Added 68.9%	14,863 $828,000
Q1 2020 Apr 27, 2020	SELL	$46.4 - $67.43 $281,323 - $408,828	-6,063 Reduced 40.79%	8,800 $562,000
Q3 2018 Nov 13, 2018	SELL	$55.19 - $62.25 $20,696 - $23,343	-375 Reduced 2.46%	14,863 $923,000
Q2 2017 Aug 14, 2017	BUY	N/A	15,238	15,238 $849,000

2,468

1.5B

29.6M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $116B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Saybrook Capital , based on Form 13F filings with the SEC.

Stay updated on Saybrook Capital with notifications on news.